Findings of Scientific Misconduct, 34690 [E7-12170]

Download as PDF 34690 Federal Register / Vol. 72, No. 121 / Monday, June 25, 2007 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES II. Award Information Office of the Secretary Administration on Aging Findings of Scientific Misconduct Availability of Funding Opportunity Announcement These grants will be issued as Cooperative Agreements because AoA anticipates having substantial involvement with the recipients during performance of funded activities. This involvement may include: assisting the project leadership in understanding the strategic goals and objectives, policy perspectives, and priorities of the Assistant Secretary for Aging and the AoA by sharing such information on an ongoing basis via e-mail, conference calls, briefings, and other consultations; providing technical assistance and support on grant management and implementation issues, including execution of the cooperative agreement; defining project performance criteria and expectations; and, monitoring, evaluating and supporting the projects’ efforts in achieving performance goals. Office of the Secretary, HHS. Notice. AGENCY: sroberts on PROD1PC70 with NOTICES ACTION: SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Diana Layman, University of Oklahoma Health Sciences Center: Based on the report of an investigation conducted by the University of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Ms. Diana Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755. Specifically, Ms. Layman falsified research in the TEAL study by substituting or conspiring with another phlebotomist to substitute her blood or blood of another phlebotomist for blood samples of 10–15 child participants in the TEAL study. Ms. Layman has entered into a Voluntary Exclusion Agreement (Agreement) in which she has voluntarily agreed, for a period of three (3) years, beginning on May 30, 2007: (1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in HHS’ implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and (2) To exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John E. Dahlberg, Acting Director, Office of Research Integrity. [FR Doc. E7–12170 Filed 6–22–07; 8:45 am] BILLING CODE 4150–31–P VerDate Aug<31>2005 23:08 Jun 22, 2007 Jkt 211001 Purpose of Notice: Availability of funding opportunity announcement. Funding Opportunity Title/Program Name: Nursing Home Diversion Modernization Grant. Announcement Type: Initial Announcement. Funding Opportunity Number: HHS– 2006–AoA–CD–0713. Statutory Authority: The Older Americans Act, Public Law 109–365. Catalog of Federal Domestic Assistance (CFDA) Number: 93.048, Title IV and Title II, Discretionary Projects. The deadline date for the submission of applications is August 24, 2007. DATES: I. Funding Opportunity Description This Program Announcement provides an opportunity for State Units on Aging (SUA) in partnership with Area Agencies on Aging (AAA) to collaborate with aging service provider organizations, and other long-term care stakeholders to modernize and transform their existing Older Americans Act Title IIIB, IIIE, and Alzheimer’s Disease Demonstration Grant (ADDGS) funds, and other nonMedicaid state revenue sources, into flexible, consumer directed service dollars that support nursing home diversion programs consistent with the standards described on the Nursing Home Diversion Modernization Grant Announcement Resource Page (https:// www.aoa.gov/doingbus/fundopp/ announcements/2007/ NHDP_Resource_Page.doc). While statewide implementation of nursing home diversion programs should be a long-term goal of programs funded under this announcement, a SUA, working with at least one AAA, may propose a project within the AAA’s geographic area of the state. States with a single Planning and Service Area (PSA) may propose activities targeted to a single county or region of the state. A detailed description of the funding opportunity may be found at https:// www.grants.gov or at https:// www.aoa.gov on the AoA Grant Programs Funding Opportunity webpage (https://aoa.gov/doingbus/fundopp/ fundopp.asp). PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 1. Funding Instrument Type 2. Anticipated Total Priority Area Funding per Budget Period AoA intends to make available, under this program announcement, grant awards for up to $500,000 each for to up to 12 States at a total federal share of approximately $5,000,000 for an 18 month project period. III. Eligibility Criteria and Other Requirements 1. Eligible Applicants Eligibility for grant awards is limited to State Units on Aging. 2. Cost Sharing or Matching Grantees are required to provide at least 25 percent of the total program costs from non-federal cash or in-kind resources in order to be considered for the award. 3. DUNS Number All grant applicants must obtain a D–U–N–S number from Dun and Bradstreet. It is a nine-digit identification number, which provides unique identifiers of single business entities. The D–U–N–S number is free and easy to obtain from https:// www.dnb.com/US/duns_update/. 4. Intergovernmental Review Executive Order 12372, Intergovernmental Review of Federal Programs, is not applicable to these grant applications. IV. Application and Submission Information 1. Address To Request Application Application kits are available by writing to the U.S. Department of Health E:\FR\FM\25JNN1.SGM 25JNN1

Agencies

[Federal Register Volume 72, Number 121 (Monday, June 25, 2007)]
[Notices]
[Page 34690]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12170]



[[Page 34690]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Diana Layman, University of Oklahoma Health Sciences Center: Based 
on the report of an investigation conducted by the University of 
Oklahoma Health Sciences Center (OUHSC) and additional analysis 
conducted by the Office of Research Integrity during its oversight 
review, the U.S. Public Health Service (PHS) found that Ms. Diana 
Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged 
in scientific misconduct in research supported by National Institute of 
Environmental Health Sciences (NIEHS), National Institutes of Health 
(NIH), grant R01 ES008755.
    Specifically, Ms. Layman falsified research in the TEAL study by 
substituting or conspiring with another phlebotomist to substitute her 
blood or blood of another phlebotomist for blood samples of 10-15 child 
participants in the TEAL study. Ms. Layman has entered into a Voluntary 
Exclusion Agreement (Agreement) in which she has voluntarily agreed, 
for a period of three (3) years, beginning on May 30, 2007:
    (1) To exclude herself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
as defined in HHS' implementation of OMB Guidelines to Agencies on 
Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and
    (2) To exclude herself from serving in any advisory capacity to 
PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John E. Dahlberg,
Acting Director, Office of Research Integrity.
 [FR Doc. E7-12170 Filed 6-22-07; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.